NEW HAVEN, Conn., June 27 (UPI) -- Dermatologists at Yale University's School of Medicine may have determined that a pre-existing arthritis drug can be used to reverse the effects of vitiligo, a skin condition involving the loss of pigmentation.
A 53-year-old patient with the disfiguring condition has regained most of her skin's pigmentation after just five months of taking a Janus kinase (JAK) inhibitor called tofacitinib citrate.